Aprea Therapeutics, Inc. APRE
Regular-session close
After hours · Nov 19, 5:42 PM ET
- YTD
- -42.19%
- 1 year
- -58.91%
5D +0.0031 (+0.69%)
- Market cap
- 7.00M
- Revenue (ttm)
- 1.28M
- EPS (ttm)
- -0.57
- Shares out
- 5.43M
- Forward P/E
- -3.08
- YTD return
- -42.19%
- 1-year return
- -58.91%
- 50-day average
- 3.48
- 200-day average
- 4.17
- Volume
- 174.08K
- Avg volume
- 348.65K
- Open
- 0.4606
- Previous close
- 0.4649
- Day's range
- 0.4549 – 0.4995
- 52-week range
- 0.39 – 1.49
- Beta
- 1.74
- Analysts
- Buy
- Price target
- 15.67 (+3077.2%)
Key statistics
- Enterprise value
- -5.20M
- Price / sales
- 13.38
- Price / book
- 0.69
- Revenue growth
- 124.90%
- Free cash flow
- -9.36M
- Total cash
- 28.69M
- Return on equity
- -50.11%
- Short % of float
- 0.38%
Fundamental scorecard
7 of 25 checks passed on APRE’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.75 | -0.64 | +0.11 | +14.67% |
| Aug 12, 2024 | Jun 1, 2024 | -0.64 | -0.58 | +0.06 | +9.38% |
| Aug 12, 2024 | Jun 1, 2024 | -0.64 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.78 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.78 | -0.67 | +0.11 | +14.10% |
| Mar 26, 2024 | Dec 1, 2023 | -0.56 | -0.92 | -0.36 | -64.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | Wedbush | reit | Outperform | Outperform |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aprea.com
News
Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock Has Consensus Price Target of $2.80 According to Brokerages
Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference Aprea Therapeutics Q3 EPS $(0.09) Misses $(0.07) Estimate
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
Aprea Therapeutics to Present at October Conferences
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Your note
Sign in to keep a note on APRE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DUEY MARC | Director | Sale | Oct 17, 2024 | 234,253 |
| GILAD OREN PH.D. | Chief Executive Officer | Purchase | Oct 22, 2024 | 335,195 |
| GRISSINGER MICHAEL J. | Director | Stock Award(Grant) | Jun 19, 2024 | 1,844 |
| HAMILL JOHN P | Chief Financial Officer | Purchase | Oct 10, 2024 | 19,368 |
| HENNEMAN JOHN BELL III | Director | Stock Award(Grant) | Jun 19, 2024 | 9,184 |
| MIRZA NADEEM Q. | Officer | Stock Award(Grant) | Apr 30, 2024 | 6,730 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 9.92% | 539,300 | 1.69M | Sep 29, 2024 |
| Sio Capital Management, LLC | 5.09% | 276,603 | 868.53K | Sep 29, 2024 |
| Sphera Funds Management Ltd. | 4.97% | 270,000 | 847.80K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 3.79% | 205,760 | 646.09K | Sep 29, 2024 |
| Vanguard Group Inc | 3.20% | 173,842 | 545.86K | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 2.52% | 137,174 | 430.73K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.67% | 145,280 | 456.18K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.53% | 28,562 | 89.68K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.47% | 25,275 | 79.36K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 7,197 | 22.60K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 5,963 | 18.72K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.09% | 5,083 | 15.96K | Jul 30, 2024 |
